Biopharma Co. Regulus Dodges Stock Suit Over Drug Trials
Biopharmaceutical company Regulus Therapeutics Inc. is no longer facing a stock-drop suit brought in California federal court related to the company's failure to secure approval for a hepatitis C treatment....To view the full article, register now.
Already a subscriber? Click here to view full article